2015-‐09-‐14 0500 PT -‐ News Release
VP Close 2015-‐09-‐11 C$ 0.10
Mr. Otto Folprecht reports
VODIS PHARMACEUTICALS INC. ANNOUNCES $250,000 NON- ‐BROKERED FINANCING
September 14th, 2015 - Vancouver, British Columbia – Vodis Pharmaceuticals Inc. (the
“Company” or “Vodis”) (CSE: VP / FSE: 1JV) wishes to announce a non-brokered private
placement offering up to 2,500,000 units of the Company (the “Units”) at a subscription price of
$0.10 per Unit for aggregate gross proceeds of $250,000 (the “Offering”).
The Offering is subject to certain conditions including, but not limited to, the receipt of all
necessary regulatory approvals. Each Unit shall consist of one common share of the Company
and one share purchase warrant (“Warrant”). Each whole Warrant will entitle the holder to
purchase one common share of the Company at a price of $0.15 for a period of 24 months
following the closing date of the Offering.
Once resale restrictions have expired and the Company’s shares have traded for 10
consecutive trading days above $1.00 Vodis may give notice that the Warrants will expire within
30 days from the day of providing notice via a news release.
In addition the Company will pay a finders fee in accordance with the regulatory guidelines.
The proceeds of the private placement will be used for expansion into Washington State, USA
and general working capital purposes.
About Vodis Pharmaceutics Inc.
Vodis is one of North Americas foremost brand names in the medical and recreational
marijuana business with operations in both the US and Canada. Its master grow teams have
consistently won or placed at each competition they have entered with their “VIP” brand. The
Company, with facilities in BC and Washington State, is also actively looking into expansion
opportunities in other countries and US states.
For further information please contact:
Head of Corporate Communications
Vodis Pharmaceuticals Inc.
8788 River Road
Delta, BC V4G 1B5
Direct: 1-866-210-1420 ext. 110
While Vodis and its subsidiaries cannot have any interest whatsoever in any proceeds as a
result of production, processing or retail activities in the United States, it can license its brand,
production and consulting services to approved Washington State license holders to ensure that
all products produced under the Vodis Pharmaceuticals program and/or associated under the
VIP brand meet or exceed the Vodis brand quality standards.
The Canadian Securities Exchange has neither approved nor disapproved the contents
of this news release and accepts no responsibility for the adequacy or accuracy hereof.
Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “expects” or “it is expected”, or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including: the use of proceeds of the Offering, the receipt of all necessary regulatory approvals. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward looking information. The Company does not undertake to update any forward-looking statements or forward-looking information that is incorporated by reference herein, except as required by applicable securities laws
- Page 1 of 61